Invasive fungal infection in children undergoing chemotherapy for cancer

Ting C. Yeh, Hsi C. Liu, Lin Y. Wang, Shu Huey Chen, Der Cherng Liang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: In children with cancer, invasive fungal infection is a serious complication of anticancer therapy. Successful treatment is a major challenge for clinical oncologists. Methods: The records of all episodes of invasive fungal infection occurring in children with cancer undergoing chemotherapy at Mackay Memorial Hospital, Taipei between January 1987 and October 2005 were reviewed. The following were documented: general characteristics, clinical presentation, predisposing factors, pathogens, antifungal treatment, association with anticancer therapy and outcome. We endeavoured to preserve renal function by administration of new antifungal agents. Anticancer therapy was given as soon as possible after diagnosis and the dose of chemotherapeutic agents was adjusted as required to prevent unduly prolonged interruption of chemotherapy and minimise the risk of leukaemia relapse. Results: Twenty-six patients with 29 episodes of invasive fungal infection were reviewed. Candida species were the leading pathogens (14/ 29) followed by Aspergillus species (11/29). In six episodes there was both visceral dissemination and fungaemia. In 23/29 patients, antibiotic therapy preceded fungal infection with a median of 11 days. Three children died from extensive fungal infection and four from progression of malignancy; the remainder survived with a median follow-up of 40 months (range 12-233). The actuarial 12-month survival rate was 87%; in patients with invasive candidiasis and aspergillosis the rates were 75% and 100%, respectively. Conclusions: In children with cancer, most invasive fungal infections can be treated successfully. Current antifungal prophylaxis should protect patients from fungal infection.

Original languageEnglish
Pages (from-to)141-147
Number of pages7
JournalAnnals of Tropical Paediatrics
Volume27
Issue number2
DOIs
Publication statusPublished - Jun 2007
Externally publishedYes

Fingerprint

Drug Therapy
Mycoses
Neoplasms
Therapeutics
Invasive Candidiasis
Fungemia
Aspergillosis
Antifungal Agents
Aspergillus
Candida
Causality
Invasive Fungal Infections
Leukemia
Survival Rate
Anti-Bacterial Agents
Kidney
Recurrence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Invasive fungal infection in children undergoing chemotherapy for cancer. / Yeh, Ting C.; Liu, Hsi C.; Wang, Lin Y.; Chen, Shu Huey; Liang, Der Cherng.

In: Annals of Tropical Paediatrics, Vol. 27, No. 2, 06.2007, p. 141-147.

Research output: Contribution to journalArticle

Yeh, Ting C. ; Liu, Hsi C. ; Wang, Lin Y. ; Chen, Shu Huey ; Liang, Der Cherng. / Invasive fungal infection in children undergoing chemotherapy for cancer. In: Annals of Tropical Paediatrics. 2007 ; Vol. 27, No. 2. pp. 141-147.
@article{e57ddce47b22433dbf1026a6998cf65b,
title = "Invasive fungal infection in children undergoing chemotherapy for cancer",
abstract = "Background: In children with cancer, invasive fungal infection is a serious complication of anticancer therapy. Successful treatment is a major challenge for clinical oncologists. Methods: The records of all episodes of invasive fungal infection occurring in children with cancer undergoing chemotherapy at Mackay Memorial Hospital, Taipei between January 1987 and October 2005 were reviewed. The following were documented: general characteristics, clinical presentation, predisposing factors, pathogens, antifungal treatment, association with anticancer therapy and outcome. We endeavoured to preserve renal function by administration of new antifungal agents. Anticancer therapy was given as soon as possible after diagnosis and the dose of chemotherapeutic agents was adjusted as required to prevent unduly prolonged interruption of chemotherapy and minimise the risk of leukaemia relapse. Results: Twenty-six patients with 29 episodes of invasive fungal infection were reviewed. Candida species were the leading pathogens (14/ 29) followed by Aspergillus species (11/29). In six episodes there was both visceral dissemination and fungaemia. In 23/29 patients, antibiotic therapy preceded fungal infection with a median of 11 days. Three children died from extensive fungal infection and four from progression of malignancy; the remainder survived with a median follow-up of 40 months (range 12-233). The actuarial 12-month survival rate was 87{\%}; in patients with invasive candidiasis and aspergillosis the rates were 75{\%} and 100{\%}, respectively. Conclusions: In children with cancer, most invasive fungal infections can be treated successfully. Current antifungal prophylaxis should protect patients from fungal infection.",
author = "Yeh, {Ting C.} and Liu, {Hsi C.} and Wang, {Lin Y.} and Chen, {Shu Huey} and Liang, {Der Cherng}",
year = "2007",
month = "6",
doi = "10.1179/146532807X192516",
language = "English",
volume = "27",
pages = "141--147",
journal = "Paediatrics and international child health",
issn = "2046-9047",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Invasive fungal infection in children undergoing chemotherapy for cancer

AU - Yeh, Ting C.

AU - Liu, Hsi C.

AU - Wang, Lin Y.

AU - Chen, Shu Huey

AU - Liang, Der Cherng

PY - 2007/6

Y1 - 2007/6

N2 - Background: In children with cancer, invasive fungal infection is a serious complication of anticancer therapy. Successful treatment is a major challenge for clinical oncologists. Methods: The records of all episodes of invasive fungal infection occurring in children with cancer undergoing chemotherapy at Mackay Memorial Hospital, Taipei between January 1987 and October 2005 were reviewed. The following were documented: general characteristics, clinical presentation, predisposing factors, pathogens, antifungal treatment, association with anticancer therapy and outcome. We endeavoured to preserve renal function by administration of new antifungal agents. Anticancer therapy was given as soon as possible after diagnosis and the dose of chemotherapeutic agents was adjusted as required to prevent unduly prolonged interruption of chemotherapy and minimise the risk of leukaemia relapse. Results: Twenty-six patients with 29 episodes of invasive fungal infection were reviewed. Candida species were the leading pathogens (14/ 29) followed by Aspergillus species (11/29). In six episodes there was both visceral dissemination and fungaemia. In 23/29 patients, antibiotic therapy preceded fungal infection with a median of 11 days. Three children died from extensive fungal infection and four from progression of malignancy; the remainder survived with a median follow-up of 40 months (range 12-233). The actuarial 12-month survival rate was 87%; in patients with invasive candidiasis and aspergillosis the rates were 75% and 100%, respectively. Conclusions: In children with cancer, most invasive fungal infections can be treated successfully. Current antifungal prophylaxis should protect patients from fungal infection.

AB - Background: In children with cancer, invasive fungal infection is a serious complication of anticancer therapy. Successful treatment is a major challenge for clinical oncologists. Methods: The records of all episodes of invasive fungal infection occurring in children with cancer undergoing chemotherapy at Mackay Memorial Hospital, Taipei between January 1987 and October 2005 were reviewed. The following were documented: general characteristics, clinical presentation, predisposing factors, pathogens, antifungal treatment, association with anticancer therapy and outcome. We endeavoured to preserve renal function by administration of new antifungal agents. Anticancer therapy was given as soon as possible after diagnosis and the dose of chemotherapeutic agents was adjusted as required to prevent unduly prolonged interruption of chemotherapy and minimise the risk of leukaemia relapse. Results: Twenty-six patients with 29 episodes of invasive fungal infection were reviewed. Candida species were the leading pathogens (14/ 29) followed by Aspergillus species (11/29). In six episodes there was both visceral dissemination and fungaemia. In 23/29 patients, antibiotic therapy preceded fungal infection with a median of 11 days. Three children died from extensive fungal infection and four from progression of malignancy; the remainder survived with a median follow-up of 40 months (range 12-233). The actuarial 12-month survival rate was 87%; in patients with invasive candidiasis and aspergillosis the rates were 75% and 100%, respectively. Conclusions: In children with cancer, most invasive fungal infections can be treated successfully. Current antifungal prophylaxis should protect patients from fungal infection.

UR - http://www.scopus.com/inward/record.url?scp=34547654436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547654436&partnerID=8YFLogxK

U2 - 10.1179/146532807X192516

DO - 10.1179/146532807X192516

M3 - Article

C2 - 17565811

AN - SCOPUS:34547654436

VL - 27

SP - 141

EP - 147

JO - Paediatrics and international child health

JF - Paediatrics and international child health

SN - 2046-9047

IS - 2

ER -